Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Rating of “Hold” by Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $16.25.

A number of equities analysts have recently commented on MD shares. Deutsche Bank Aktiengesellschaft raised their price target on Pediatrix Medical Group from $9.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Mizuho raised their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. StockNews.com lowered Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, December 19th. UBS Group increased their price target on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Macquarie initiated coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company.

Pediatrix Medical Group Stock Down 2.5 %

MD stock opened at $12.81 on Tuesday. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $16.41. The stock has a fifty day moving average of $14.35 and a 200-day moving average of $11.49. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.19, a PEG ratio of 2.00 and a beta of 1.58. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.29 earnings per share. As a group, equities research analysts predict that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the business’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Pediatrix Medical Group

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Nordea Investment Management AB grew its holdings in Pediatrix Medical Group by 51.6% in the 4th quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock worth $3,504,000 after acquiring an additional 89,739 shares during the last quarter. Everence Capital Management Inc. grew its stake in shares of Pediatrix Medical Group by 7.5% in the fourth quarter. Everence Capital Management Inc. now owns 13,840 shares of the company’s stock worth $182,000 after purchasing an additional 960 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Pediatrix Medical Group by 14.1% during the 3rd quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after purchasing an additional 63,581 shares during the period. Franklin Resources Inc. bought a new position in Pediatrix Medical Group during the 3rd quarter valued at approximately $598,000. Finally, Barclays PLC lifted its holdings in Pediatrix Medical Group by 302.9% in the 3rd quarter. Barclays PLC now owns 142,087 shares of the company’s stock worth $1,646,000 after buying an additional 106,817 shares during the period. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.